Similar articles for PMID: 20522448

1

Cite

Share

Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study.

Sumiyoshi Y, Hashine K, Kakehi Y, Yoshimura K, Satou T, Kuruma H, Namiki S, Shinohara N. Sumiyoshi Y, et al. Jpn J Clin Oncol. 2010 Oct;40(10):967-72. doi: 10.1093/jjco/hyq081. Epub 2010 Jun 3. Jpn J Clin Oncol. 2010. PMID: 20522448 Clinical Trial.

Cite

Share

2

Cite

Share

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Ryan CJ, et al. J Urol. 2007 Dec;178(6):2372-6; discussion 2377. doi: 10.1016/j.juro.2007.08.011. Epub 2007 Oct 22. J Urol. 2007. PMID: 17936834 Clinical Trial.

Cite

Share

3

Cite

Share

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.

Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group. Gittelman M, et al. J Urol. 2008 Nov;180(5):1986-92. doi: 10.1016/j.juro.2008.07.033. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801505 Clinical Trial.

Cite

Share

4

Cite

Share

A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.

Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W; North Central Cancer Treatment Group. Jatoi A, et al. Urology. 2007 Feb;69(2):289-94. doi: 10.1016/j.urology.2006.10.019. Urology. 2007. PMID: 17320666 Clinical Trial.

Cite

Share

5

Cite

Share

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ. Urba WJ, et al. J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801509 Clinical Trial.

Cite

Share

6

Cite

Share

Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones.

Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP. Jarred RA, et al. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1689-96. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12496063 Clinical Trial.

Cite

Share

7

Cite

Share

Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.

Grande M, Carlström K, Rozell BL, Stege R, Pousette A. Grande M, et al. Clin Cancer Res. 2000 May;6(5):1790-5. Clin Cancer Res. 2000. PMID: 10815899 Clinical Trial.

Cite

Share

8

Cite

Share

Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH. Rademaker-Lakhai JM, et al. Clin Cancer Res. 2005 Mar 1;11(5):1854-62. doi: 10.1158/1078-0432.CCR-04-1534. Clin Cancer Res. 2005. PMID: 15756010 Clinical Trial.

Cite

Share

9

Cite

Share

[A clinical analysis of patients with early-stage prostate cancer managed without initial treatment].

Kawa G, Hiura Y, Satoh H, Sugi M, Fujita I, Oguchi N, Doi H, Ashida M, Okada H, Muguruma K, Murota T, Koyama Y, Kawamura H, Ohara T, Kawakita M, Matsuda T. Kawa G, et al. Hinyokika Kiyo. 2002 Mar;48(3):133-8. Hinyokika Kiyo. 2002. PMID: 11993205 Free article. Japanese.

Cite

Share

10

Cite

Share

Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.

Ansari MS, Gupta NP. Ansari MS, et al. Urol Oncol. 2004 Sep-Oct;22(5):415-20. doi: 10.1016/j.urolonc.2004.05.009. Urol Oncol. 2004. PMID: 15464923 Clinical Trial.

Cite

Share